Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01926990 · ClinicalTrials.gov registry record
Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 19
- Enrollment target
NCT01926990: Completed study, sponsored by Stanford University.
NCT01926990 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01926990 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Interventions
- DEVICE perfusion computed tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-08 |
| Est. Completion | 2021-12-17 |
What the finished NCT01926990 record still lists
NCT01926990 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which perfusion computed tomography is the first listed.
NCT01926990 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01926990 about?
NCT01926990 is a clinical study titled "Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma". This pilot clinical trial studies perfusion computed tomography (CT) in predicting response to treatment in patients with advanced kidney cancer. Comparing results of diagnostic procedures done before, during, and after targeted therapy may help doctors predict a patient's response to treatment and ...
What is the current status of trial NCT01926990?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2014-08. Estimated completion is 2021-12-17.
What interventions are being tested in trial NCT01926990?
The interventions under investigation include: perfusion computed tomography (DEVICE).
Who is sponsoring clinical trial NCT01926990?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia